Article Text

Download PDFPDF
113 Analysis of clinical and angiogenesis factors with cervical cancer stage IB2 And IIA2 neo-adjuvant chemotherapy responses
  1. Syamel Muhammad1,
  2. Restu Susanti1,
  3. Yudi Mulyana Hidayat2 and
  4. Diniy Miftahul Muthmainnah1
  1. 1Universitas Andalas, Padang, Indonesia
  2. 2Padjajaran University, Bandung, Indonesia


Introduction/Background Cervical cancer is a malignancy in the lower part of the uterus and is the fourth most common female cancer in the world and the second largest in Indonesia. Optimal management of ‘bulky’ cervical cancer stage IB2 and IIA2 is controversial; the administration of neoadjuvant chemotherapy before definitive treatment can reduce recurrence and good therapeutic response, but for resistant patients, neoadjuvant chemotherapy will delay definitive therapy. A marker is needed to identify which patients are resistant to chemotherapy. Clinical factors and angiogenesis factors are known to affect therapy. This study is to analyze clinical factors (tumor size, hemoglobin, age, parity, histological type and differentiation) and angiogenesis factors (HIF1-alpha, VEGF, microvascular density and Cervix Vascular Doppler Ultrasound) effect on neoadjuvant chemotherapy response of IB2 and IIA2 cervical cancer

Methodology Cohort analytic research has been conducted at Dr. M Djamil Central Hospital Padang Indonesia with 35 cervical cancer stage IB2 and IIA2 patients who were given neoadjuvant chemotherapy. Clinical factors and angiogenesis factors were examined and recorded before being given chemotherapy. HIF1-Alfa, VEGF and Microvascular density (MVD) measure using immunohistochemical methods in cervical cancer biopsy tissue, chemotherapy response based on RECIST criteria (measurements of the longest diameter of the tumor before and after neoadjuvant chemotherapy) using transrectal ultrasound

Results The results of 35 patients showed that a good chemotherapy response was found in 80% of cases. Statistical analysis showed that only angiogenesis (Doppler and VEGF) factors (p <0.05) significantly affected the neoadjuvant chemotherapy response of IB2 and IIA2 cervical cancer.

Conclusion Angiogenesis factors (Doppler ultrasound and MVD) have significant impact on tumor size reduction in neoadjuvant chemotherapy for cervical cancer stage IB2 and IIA2

Disclosures No Disclosures.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.